دورية أكاديمية

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.

التفاصيل البيبلوغرافية
العنوان: Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
المؤلفون: Coombes, R C, Bliss, J M, Espie, M, Erdkamp, F, Wals, J, Tres, A, Marty, M, Coleman, R E, Tubiana-Mathieu, N, den Boer, M O, Wardley, Andrew M, Kilburn, L S, Cooper, D, Thomas, M W K, Reise, J A, Wilkinson, K, Hupperets, P
المساهمون: Division of Cancer, Imperial College London, London, United Kingdom. c.coombes@imperial.ac.uk
سنة النشر: 2011
المجموعة: The Christie School of Oncology: Christie Research Publications Repository
مصطلحات موضوعية: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Disease-Free Survival, Drug Administration Schedule, Epirubicin, Female, Humans, Lymphatic Metastasis, Middle Aged, Neoplasms, Second Primary, Quality of Life, Selective Estrogen Receptor Modulators, Tamoxifen, Taxoids
الوصف: The Docetaxel Epirubicin Adjuvant (DEVA) trial evaluated the efficacy and toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane regimen in early breast cancer.
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 1527-7755
العلاقة: Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. 2011, 29 (24):3247-54 J. Clin. Oncol.; http://hdl.handle.net/10541/229165Test; Journal of Clinical Oncology
DOI: 10.1200/JCO.2010.32.7254
الإتاحة: https://doi.org/10.1200/JCO.2010.32.7254Test
http://hdl.handle.net/10541/229165Test
حقوق: Archived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncology
رقم الانضمام: edsbas.24DE6037
قاعدة البيانات: BASE
الوصف
تدمد:15277755
DOI:10.1200/JCO.2010.32.7254